Profile data is unavailable for this security.
About the company
Mural Oncology plc is a clinical-stage oncology company. The Company is leveraging its protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. It leverages its expertise in cytokine biology, immune cell modulation and protein engineering capabilities to develop immunotherapies. The Company is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available. Its portfolio of programs includes Nemvaleukin alfa (Nemvaleukin)-IL-2, IL-12, and IL-18. Nemvaleukin is an engineered interleukin-2 (IL-2) variant designed to harness the potent anti-cancer capabilities of high-dose rhIL-2 while minimizing toxicity by selectively activating cancer-fighting CD8 T cells and NK cells. The tumor-targeted split IL-12 program focuses on delivering the therapeutic potential of IL-12 by splitting it into inactive component.
- Revenue in USD (TTM)0.00
- Net income in USD-191.90m
- Incorporated2017
- Employees117.00
- LocationMural Oncology PLC10 Earlsfort TerraceDUBLIN D02 T380IrelandIRL
- Phone+353 19058020
- Websitehttps://www.muraloncology.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DURECT Corp | 8.32m | -23.28m | 51.68m | 48.00 | -- | 6.23 | -- | 6.21 | -0.8653 | -0.8653 | 0.2976 | 0.2674 | 0.176 | 0.7021 | 6.87 | 143,465.50 | -49.23 | -37.34 | -167.81 | -53.44 | 80.56 | 91.83 | -279.77 | -139.11 | 0.9575 | -47.70 | 0.6377 | -- | -55.67 | -10.96 | 21.82 | -- | -10.98 | -- |
LAVA Therapeutics NV | 12.54m | -28.59m | 52.05m | 37.00 | -- | 1.03 | -- | 4.15 | -1.07 | -1.07 | 0.4668 | 1.93 | 0.107 | -- | 9.09 | 338,837.80 | -24.40 | -- | -28.91 | -- | 79.64 | -- | -228.02 | -- | -- | -- | 0.108 | -- | -65.09 | -- | -31.55 | -- | -- | -- |
Inotiv Inc | 552.74m | -71.29m | 52.20m | 1.96k | -- | 0.2514 | -- | 0.0944 | -2.77 | -2.77 | 21.44 | 8.00 | 0.6565 | 7.18 | 7.91 | 282,733.50 | -8.58 | -23.84 | -13.63 | -29.26 | 28.76 | 29.31 | -13.07 | -33.24 | 0.2744 | -0.0193 | 0.6476 | -- | 4.52 | 85.10 | 68.80 | -- | 83.64 | -- |
Rallybio Corp | 0.00 | -76.28m | 53.88m | 43.00 | -- | 0.5513 | -- | -- | -1.88 | -1.88 | 0.00 | 2.36 | 0.00 | -- | -- | 0.00 | -58.30 | -- | -62.32 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.87 | -- | -- | -- |
Aerovate Therapeutics Inc | 0.00 | -82.19m | 54.45m | 51.00 | -- | 0.58 | -- | -- | -3.03 | -3.03 | 0.00 | 3.26 | 0.00 | -- | -- | 0.00 | -71.09 | -- | -80.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -46.61 | -- | -- | -- |
Aileron Therapeutics Inc | 0.00 | -18.07m | 57.28m | 15.00 | -- | 0.9974 | -- | -- | -3.19 | -3.19 | 0.00 | 5.42 | 0.00 | -- | -- | 0.00 | -31.05 | -65.99 | -33.17 | -75.37 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
Mural Oncology PLC | 0.00 | -191.90m | 58.05m | 117.00 | -- | 0.2471 | -- | -- | -11.49 | -11.49 | 0.00 | 13.88 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.29 | -- | -- | -- |
Estrella Immunopharma Inc | 0.00 | -2.16m | 58.20m | -- | -- | 5.59 | -- | -- | -1.90 | -1.90 | 0.00 | 0.2861 | 0.00 | -- | -- | -- | -5.92 | -- | -7.86 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -302.11 | -- | -- | -- |
Enzo Biochem Inc | 33.34m | -17.55m | 60.21m | 179.00 | -- | 0.8683 | -- | 1.81 | -0.3516 | 0.9194 | 0.6633 | 1.35 | 0.4028 | 1.66 | 4.91 | 186,257.00 | -21.20 | -12.21 | -34.50 | -15.79 | 43.66 | 37.09 | -52.63 | -18.76 | 3.16 | -- | 0.053 | -- | -4.85 | -21.01 | -23.02 | -- | 7.89 | -- |
VolitionRX Ltd | 797.03k | -34.91m | 61.74m | 110.00 | -- | -- | -- | 77.46 | -0.4603 | -0.4603 | 0.0104 | -0.1901 | 0.0425 | -- | 6.32 | 7,245.73 | -188.25 | -111.92 | -- | -196.20 | -- | -- | -4,425.95 | -10,793.31 | -- | -173.85 | -- | -- | 153.04 | -- | -16.68 | -- | 29.13 | -- |
Anebulo Pharmaceuticals Inc | 0.00 | -9.35m | 62.24m | 2.00 | -- | 12.48 | -- | -- | -0.3633 | -0.3633 | 0.00 | 0.1922 | 0.00 | -- | -- | 0.00 | -91.51 | -- | -104.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.89 | -- | -- | -- |
RetinalGenix Technologies Inc | 0.00 | -3.73m | 62.51m | 0.00 | -- | -- | -- | -- | -0.2124 | -0.2124 | 0.00 | -0.085 | 0.00 | -- | -- | -- | -12,800.17 | -9,163.75 | -- | -- | -- | -- | -- | -- | -- | -969.35 | -- | -- | -- | -- | 46.58 | -- | -- | -- |
Vor Biopharma Inc | 0.00 | -120.23m | 64.49m | 168.00 | -- | 0.5238 | -- | -- | -1.78 | -1.78 | 0.00 | 1.80 | 0.00 | -- | -- | 0.00 | -54.09 | -45.79 | -57.42 | -48.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.98 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Armistice Capital LLCas of 31 Mar 2024 | 1.66m | 9.80% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 1.01m | 5.95% |
DUMAC, Inc.as of 01 Apr 2024 | 1.00m | 5.93% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 920.47k | 5.44% |
Verition Fund Management LLCas of 31 Mar 2024 | 792.47k | 4.68% |
Solas Capital Management LLCas of 31 Mar 2024 | 748.96k | 4.43% |
Westfield Capital Management Co. LPas of 28 Jun 2024 | 743.50k | 4.39% |
Alta Fundamental Advisers LLCas of 31 Mar 2024 | 723.26k | 4.27% |
Newtyn Management LLCas of 31 Mar 2024 | 500.00k | 2.95% |
Prosight Management LPas of 31 Mar 2024 | 400.00k | 2.36% |